EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Simultaneous molecular detection of Mycobacterium tuberculosis and multidrug resistance using CRISPR-AaCas12b-based nucleic acid assay

Yujiao Hu, Dan Zhao, Yanjun Diao, Congxia Bai, Ke Zhou, Fang Huang, Rui Li, Xiaoyan Hao, Hao Liu, Jiayun Liu, Lei Zhou

Frontiers in Cellular and Infection Microbiology · 2026

DOI: 10.3389/fcimb.2026.1844184 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2026. Verfasst von Yujiao Hu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, China. Hauptthemen laut MEDLINE: Mycobacterium tuberculosis, Tuberculosis, Multidrug-Resistant, Drug Resistance, Multiple, Bacterial, CRISPR-Cas Systems. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To address the unmet need for rapid, accurate diagnosis of Mycobacterium tuberculosis (MTB) and multidrug-resistant tuberculosis (MDR-TB), we developed and validated a clustered regularly interspaced short palindromic repeats-associated protein (CRISPR-Cas)-based diagnostic assay.

Methods

A multiplex-recombinase polymerase amplification (RPA) coupled CRISPR- Alicyclobacillus acidiphilus Cas12b (AaCas12b) assay was established for simultaneous detection of MTB by targeting the specific insertion sequence IS6110 and the two most common drug resistance mutations, rpoB 1349C>T for rifampicin resistance and katG 944G>C for isoniazid resistance. The assay supported dual-readout signal detection using both a fluorescent platform and lateral flow chromatography (LFC). Its diagnostic performance was evaluated in 48 clinical samples using WHO-recommended GeneXpert MTB/RIF, phenotypic drug susceptibility testing (pDST), and sequencing as reference standards.

Results

The multiplex-RPA CRISPR-AaCas12b assay showed a limit of detection (LoD) of 1.5 CFU/mL for MTB detection, with a sensitivity of 97.1% and a specificity of 100% using culture as the reference standard, and a total turnaround time of 30 min (20 min for RPA and 10 min for CRISPR cleavage). For MDR-TB-related mutations, the assay achieved a sensitivity of 94.1% and a specificity of 100% for rpoB 1349C>T, and 94.7% sensitivity and 93.1% specificity for katG 944G>C, using sequencing as the reference standard. Notably, the LFC-integrated assay maintained comparable diagnostic accuracy with a total turnaround time of 35 min (20 min for RPA, 5 min for CRISPR cleavage, and 10 min for lateral flow strip reading).

Conclusion

The established multiplex-RPA CRISPR-AaCas12b assay enables simple, accurate, and sensitive detection of MTB and common mutations associated with MDR-TB. With a rapid, simplified workflow and low resource requirements, this approach holds considerable potential for point-of-care testing in resource-limited settings, thus facilitating improved surveillance and control of TB and drug-resistant TB.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mycobacterium tuberculosisTuberculosis, Multidrug-ResistantDrug Resistance, Multiple, BacterialCRISPR-Cas SystemsMolecular Diagnostic TechniquesHumansSensitivity and SpecificityBacterial ProteinsRapid Diagnostic TestsRifampinAntitubercular AgentsClustered Regularly Interspaced Short Palindromic RepeatsDNA-Directed RNA PolymerasesMutationMicrobial Sensitivity TestsIsoniazidCatalase

Stichwörter der Autor:innen

CRISPR-AaCas12bkatG 944G>Clateral flow chromatography (LFC)multidrug-resistant tuberculosis (MDR-TB)rpoB 1349C>Ttuberculosis (TB)

Substanzen

Bacterial ProteinsRifampinAntitubercular AgentskatG protein, Mycobacterium tuberculosisDNA-Directed RNA PolymerasesrpoB protein, Mycobacterium tuberculosisIsoniazidCatalase

Autor:innen und Institutionen

  • Department of Clinical Laboratory Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
  • Department of Clinical Laboratory Medicine, Xi'an Chest Hospital, Xi'an, China.

Zitieren

APA

Hu, Y., Zhao, D., Diao, Y., Bai, C., Zhou, K., Huang, F., Li, R., Hao, X., Liu, H., Liu, J., & Zhou, L. (2026). Simultaneous molecular detection of Mycobacterium tuberculosis and multidrug resistance using CRISPR-AaCas12b-based nucleic acid assay. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2026.1844184

Vancouver

Hu Y, Zhao D, Diao Y, Bai C, Zhou K, Huang F, et al. Simultaneous molecular detection of Mycobacterium tuberculosis and multidrug resistance using CRISPR-AaCas12b-based nucleic acid assay. Frontiers in Cellular and Infection Microbiology. 2026. doi:10.3389/fcimb.2026.1844184

BibTeX
@article{Hu2026,
  author = {Hu, Yujiao and Zhao, Dan and Diao, Yanjun and Bai, Congxia and Zhou, Ke and Huang, Fang and Li, Rui and Hao, Xiaoyan and Liu, Hao and Liu, Jiayun and Zhou, Lei},
  title = {Simultaneous molecular detection of Mycobacterium tuberculosis and multidrug resistance using CRISPR-AaCas12b-based nucleic acid assay},
  journal = {Frontiers in Cellular and Infection Microbiology},
  year = {2026},
  doi = {10.3389/fcimb.2026.1844184}
}
Kostenlos starten →